Core Points - JinHua New Materials (920015) saw a significant increase of 133.00% on its first trading day, with a turnover rate of 91.23% and a transaction volume of 1.132 billion yuan [2] - The stock's first-day margin trading amounted to 17.8716 million yuan, accounting for 1.58% of the total trading volume, with a latest margin balance of 15.3305 million yuan, representing 1.17% of the circulating market value [2] Company Overview - The company primarily engages in the research, development, production, and sales of ketoxime series fine chemicals [3]

Core Insights - The Beijing Stock Exchange (BSE) is experiencing a rapid expansion phase, with a notable increase in IPO activities and subscription rates for new stocks [1][2] Group 1: Company Developments - Hangdongguang Communication Technology Co., Ltd. has met the requirements for issuance, listing, and information disclosure, and is set to proceed with its IPO [1] - The company plans to raise nearly 500 million yuan for various projects, including the expansion of its manufacturing base in Guilin and a new optical research center [2] - Hangdongguang's revenue and net profit have shown significant growth, particularly in overseas sales, which increased from 75% to approximately 90% of its main business revenue from 2022 to 2024 [2][3] Group 2: Market Performance - Zhejiang Jinhua New Materials Co., Ltd. debuted on the BSE with a remarkable first-day increase of 133%, closing at 42.29 yuan after opening at 39 yuan [4] - The company raised a total of 593 million yuan through its IPO, with a total market capitalization of 5.526 billion yuan [4] - Subscription for Jinhua New Materials reached a record high of 468 billion shares, indicating strong market demand and investor enthusiasm [5] Group 3: Industry Trends - The BSE has maintained a high frequency of new stock issuances, with a notable uptick in the pace of IPOs and subscriptions in recent weeks [1] - The average first-day return for new stocks listed on the BSE this year has exceeded 349.98%, showcasing a robust market environment for new listings [5] - The overall market sentiment remains positive, with significant liquidity and investor interest in new stock offerings [5]

Core Points - N Jinhua (920015) was listed on the Beijing Stock Exchange, opening with a significant increase of 114.88% and closing with a total gain of 133.00% [2] - The company specializes in the research, production, and sales of ketoxime series fine chemicals [2] Financial Performance - The net profits for the company are projected to be 79.59 million yuan in 2022, 173 million yuan in 2023, and 211 million yuan in 2024 [3] - The public offering consisted of 32.67 million shares at an issuance price of 18.15 yuan, resulting in a price-to-earnings ratio of 11.52 [3] Issuance Details - The online issuance volume was initially 26.13 million shares, which was increased to 31.03 million shares due to an oversubscription mechanism [3] - The effective subscription amount for the online issuance reached 46,897,366.69 million shares, with a subscription multiple of 1511.19 times and a distribution ratio of 0.07% [3] Market Performance - The trading volume for N Jinhua on its first day was 28.31 million shares, with a total transaction value of 1.132 billion yuan and a turnover rate of 91.23% [2] - A comparison of recent IPOs shows that N Jinhua's first-day closing price of 42.29 yuan represents a 133.00% increase from its issuance price [3][4]

Group 1 - The core viewpoint of the news is the successful listing of N Jinhua on the Beijing Stock Exchange, with significant initial trading performance [1][2] - The stock opened with a surge of 114.88% and reached a peak increase of 147.99% by midday, with a trading volume of 24.0942 million shares and a turnover of 950 million yuan [1] - The company specializes in the research, production, and sales of ketoxime series fine chemicals [1] Group 2 - The company's net profits for 2022, 2023, and 2024 are projected to be 79.5922 million yuan, 173 million yuan, and 211 million yuan respectively [2] - The public offering consisted of 32.6667 million shares at an issuance price of 18.15 yuan, with an issuance price-to-earnings ratio of 11.52 times [2] - The effective subscription amount for the online offering was 4.68973669 billion shares, resulting in a subscription multiple of 1511.19 times and an allocation ratio of 0.07% [2]

Core Points - N Jinhua (920015) was listed on the Beijing Stock Exchange today, opening at 39.00 yuan, an increase of 114.88% from its issue price [2] - The company specializes in the research, production, and sales of ketoxime series fine chemicals [2] - The listing application was accepted on June 21, 2024, taking a total of 461 days from acceptance to listing [2] Financial Summary - The company issued 32.67 million shares at an issue price of 18.15 yuan, with an earnings per share (EPS) ratio of 11.52 times [2] - The online issuance volume was 26.13 million shares, with an oversubscription of 49 million shares, increasing the online issuance to 31.03 million shares [2] - The effective subscription amount for this issuance was 4,689,736.69 million shares, resulting in a subscription multiple of 1511.19 times and an allocation ratio of 0.07% [2] Profit Forecast - The company's net profits for 2022, 2023, and 2024 are projected to be 79.59 million yuan, 173 million yuan, and 211 million yuan respectively [3]

Core Insights - Three companies have recently been listed on different stock exchanges, with their respective issuance prices and price-earnings ratios provided [1][2][3][4]. Group 1: Company Listings - Jianfa Zhixin was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301584, an issuance price of 7.05 CNY per share, and a price-earnings ratio of 13.29 [2]. - United Power was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301656, an issuance price of 12.48 CNY per share, and a price-earnings ratio of 32.87 [3]. - Jinhua New Materials was listed on the Beijing Stock Exchange with a stock code of 920015, an issuance price of 18.15 CNY per share, and a price-earnings ratio of 11.95 [4]. Group 2: Company Profiles - Jianfa Zhixin specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [2]. - United Power aims to be a global leader in intelligent electric vehicle components and solutions, focusing on core components of power systems such as electric drive systems and power supply systems [3]. - Jinhua New Materials is engaged in the research, production, and sales of ketoxime series fine chemicals [5].

Group 1: New Stock Performance - The recent performance of new stocks on the Beijing Stock Exchange remains highly active, with the stock of Sanxie Electric rising by over 860% on its first day of trading, closing up 785.62%, marking the highest first-day increase of the year [1] - Aifenda also saw a first-day increase of 170.03%, with a single subscription yield exceeding 16,000 yuan [1] Group 2: Upcoming IPOs - This week, there are five new stocks available for subscription, including three from the Growth Enterprise Market, one from the Shenzhen Main Board, and one from the Beijing Stock Exchange [3] - The first stock available for subscription on September 15 is United Power, a leader in the new energy vehicle power system industry, collaborating with major automotive brands [1][5] Group 3: Financial Projections - United Power expects to achieve a net profit of 750 million to 900 million yuan in the first three quarters of 2025, representing a year-on-year growth of 31.05% to 57.26% [5] - The projected revenue for United Power in the same period is between 1.4 billion and 1.55 billion yuan, indicating a growth of 30.62% to 44.61% compared to the previous year [6] Group 4: Other Companies' Projections - Jianfa Zhixin anticipates a net profit of 200 million to 222 million yuan for the first three quarters of 2025, reflecting a growth of 30% to 40% [7] - Jin Hua New Materials expects a decline in revenue to 1.063 billion yuan for the full year 2025, down 14.25%, with a net profit of 199 million yuan, a decrease of 5.47% [9] - Rui Li Ke Mi forecasts a net profit of 196 million to 220 million yuan for the first three quarters of 2025, with a growth rate of 11.96% to 25.67% [10][11] - Yunhan Xincheng projects a net profit of 77 million to 80 million yuan for the first three quarters of 2025, with a growth of 38.71% to 44.11% [12][13]

Group 1 - Company Jianfa Zhixin is offering shares for subscription with a code of 301584, an issue price of 7.05 yuan per share, and a total of 63.19 million shares available [2] - The top subscription requires a market value of 100,000 yuan, with a single account subscription limit of 10,000 shares [2] - The company specializes in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [3] Group 2 - Company Jinhua New Materials is also offering shares for subscription with a code of 920015, an issue price of 18.15 yuan per share, and a total of 32.67 million shares available [4] - The top subscription requires a market value of 28.16 million yuan, with a single account subscription limit of 1.55 million shares [4] - The company focuses on the research, production, and sales of ketoxime series fine chemicals [5] Group 3 - The number of winning subscription numbers for You Sheng Co. is 63,982, with each winning number allowing the subscription of 500 shares [6] - The winning numbers are detailed in the announcement, including various combinations of digits [7] - The final winning rate for the online issuance of United Power is 0.0328%, with a total of 13,329,409 valid subscription accounts [8][9]

Core Viewpoint - The company, JinHua New Materials, has initiated its IPO with a price of 18.15 yuan and a P/E ratio of 11.52 times, aiming to raise approximately 5.93 billion yuan for various projects [1][2]. Group 1: IPO Details - The initial issuance quantity is 32.67 million shares, with an online issuance of 26.13 million shares, and a total share capital post-issuance of 131 million shares [1][2]. - The company has authorized Zheshang Securities to allocate an additional 4.90 million shares to online investors, increasing the online issuance to 31.03 million shares [1][2]. - The strategic placement of shares amounts to 6.53 million shares, representing 20% of the initial issuance scale [1][2]. Group 2: Fundraising and Project Allocation - The total expected fundraising amount is 593 million yuan, which could increase to 682 million yuan if the overallotment option is fully exercised [1][2]. - The raised funds will be directed towards several projects, including: - 60kt/a high-end coupling agent project: 506.90 million yuan - Ketoxime silicon new materials research institute: 136.22 million yuan - Intelligent factory construction for the ketoxime industry chain: 63.11 million yuan - Marketing network construction: 38.61 million yuan - 500 tons/year JH-2 pilot project: 23 million yuan [2]. Group 3: Financial Performance - The company’s net profit for 2022, 2023, and 2024 is projected to be 79.59 million yuan, 173 million yuan, and 211 million yuan, respectively, with year-on-year changes of -67.34%, 116.74%, and 22.28% [2]. - Key financial indicators for 2024 include total assets of 1.32 billion yuan, net assets of 842.66 million yuan, and operating income of 1.24 billion yuan [3][4]. - The diluted earnings per share for 2024 is projected at 2.15 yuan, with a return on equity of 28.19% [4].

Group 1: Company Overview - The company operates as a national high-value medical device distributor, focusing on direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to hospitals [2] - As of the signing date of the prospectus, Xiamen Jianfa Medical Health Investment Co., Ltd. holds 51.02% of the company's shares, making it the controlling shareholder [2] - The actual controller of the company is the Xiamen State-owned Assets Supervision and Administration Commission, which indirectly holds 51.02% of the company's shares through its ownership of Jianfa Group and Jianfa Medical [2] Group 2: Fundraising and Financials - The company plans to raise approximately 484.24 million yuan for projects including information system upgrades, centralized operation services for medical consumables, and to supplement working capital [2] - The initial public offering (IPO) price is set at 7.05 yuan per share, with an expected total fundraising amount of 445.51 million yuan, and a net fundraising amount of approximately 363.33 million yuan after deducting issuance costs [3] Group 3: Industry Context - The company plays a crucial role in the medical device supply chain, acting as a hub that connects manufacturers, distributors, and end medical institutions [2] - The reference industry price-earnings ratio for the wholesale industry is 25.73, while the company's offering price results in a price-earnings ratio of 13.29, indicating a potential undervaluation compared to industry peers [1]